daprodustat
Trade name: Jesduvroq
Approved
Feb 1, 2023
Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth. — Wikipedia
Clinical trial activity
41 trials · 6 clinical orgs · 1 marketing orgs
Earliest trial started Jul 1, 2008 (NCT00750256)
Timeline
2000s
- Jan 1, 2008
GlaxoSmithKline — Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2010
GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2016
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
2020s
- Feb 1, 2023
GlaxoSmithKline — Earliest FDA Approval
- Feb 1, 2023
GlaxoSmithKline — Marketing Organization
- Feb 1, 2023
GlaxoSmithKline — NDA Secondary Org
- Feb 1, 2023
GlaxoSmithKline — NDA Organization
Indications
Mechanism of action
Hypoxia-inducible factor prolyl hydroxylase inhibitor
Approval history
- approvedFeb 1, 2023
Chemistry & pharmacology
SMILES
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O- Mol. weight
- 393.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaDaprodustat ↗
- ChEMBLCHEMBL3544988 ↗
Also known as
- 1278863a
- daprodustat
- daprodustat
- daprodustat
- daprodustat
- gsk1278863
- gsk1278863
- gsk1278863
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300111 | Phase 3 | Dec 31, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT05682326 | Phase 3 | Sep 6, 2023 | GlaxoSmithKline |
| NCT05951192 | Phase 4 | Jul 1, 2023 | GlaxoSmithKline, USRC Kidney Research |
| NCT04640311 | Phase 1 | Dec 17, 2020 | GlaxoSmithKline |
| NCT03446612 | Phase 2 | Oct 15, 2018 | GlaxoSmithKline |
| NCT03457701 | Phase 2 | Oct 1, 2018 | GlaxoSmithKline |
| NCT03400033 | Phase 3 | Sep 5, 2018 | GlaxoSmithKline |
| NCT03493386 | Phase 1 | Apr 24, 2018 | GlaxoSmithKline |
| NCT03409107 | Phase 3 | Mar 5, 2018 | GlaxoSmithKline |
| NCT03239522 | Phase 1 | Oct 10, 2017 | GlaxoSmithKline |
| NCT03223337 | Phase 1 | Jul 24, 2017 | GlaxoSmithKline |
| NCT03029247 | Phase 2 | Jun 30, 2017 | GlaxoSmithKline, IQVIA |
| NCT03029208 | Phase 3 | May 11, 2017 | GlaxoSmithKline |
| NCT02969655 | Phase 3 | Nov 1, 2016 | GlaxoSmithKline |
| NCT02879305 | Phase 3 | Sep 28, 2016 | GlaxoSmithKline |
| NCT02876835 | Phase 3 | Sep 27, 2016 | GlaxoSmithKline |
| NCT02829320 | Phase 3 | Aug 1, 2016 | GlaxoSmithKline |
| NCT02791763 | Phase 3 | Jun 1, 2016 | GlaxoSmithKline |
| NCT02689206 | Phase 2 | Feb 17, 2016 | GlaxoSmithKline |
| NCT02371603 | Phase 1 | Feb 11, 2015 | GlaxoSmithKline |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 40 | 39 | 4 | 2008 |
| PPD | For profit | 2 | 0 | 1 | 2012 |
| IQVIA | For profit | 1 | 0 | 1 | 2017 |
| Octagon Research Solutions, Incoporated | For profit | 1 | 0 | 1 | 2010 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| USRC Kidney Research | Academic/Hospital | 1 | 1 | 1 | 2023 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | MKTG | Feb 1, 2023 |
| GlaxoSmithKline | For profit | NDA2 | Feb 1, 2023 |
| GlaxoSmithKline | For profit | NDA | Feb 1, 2023 |